126 related articles for article (PubMed ID: 37779440)
1. Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study.
Panagiotidis E; Fragkiadaki V; Papathanasiou N; Kypraios C; Liatsikos E; Klampatsas A; Paschali A; Exarhos D; Zarokosta F; Chatzipavlidou V; Apostolopoulos D; Datseris I
Nucl Med Commun; 2023 Dec; 44(12):1126-1134. PubMed ID: 37779440
[TBL] [Abstract][Full Text] [Related]
2. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
5. PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT.
Pinot F; Le Pennec R; Abgral R; Blanc-Béguin F; Hennebicq S; Schick U; Valeri A; Fournier G; Le Roux PY; Salaun PY; Robin P
Clin Genitourin Cancer; 2023 Apr; 21(2):248-257. PubMed ID: 36658064
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
[TBL] [Abstract][Full Text] [Related]
7.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
8. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
10. Phase III Study of
Olivier P; Giraudet AL; Skanjeti A; Merlin C; Weinmann P; Rudolph I; Hoepping A; Gauthé M
J Nucl Med; 2023 Apr; 64(4):579-585. PubMed ID: 36418170
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
13.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
14.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
15. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
16. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
18.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
19.
Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
[TBL] [Abstract][Full Text] [Related]
20. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]